Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
  • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
  • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
  • C07J53/002—Carbocyclic rings fused
  • C07J53/004—3 membered carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
  • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
  • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
  • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
  • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
  • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
  • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
  • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
  • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
  • C07J71/0036—Nitrogen-containing hetero ring
  • C07J71/0042—Nitrogen only
  • C07J71/0052—Nitrogen only at position 16(17)

Definitions

• This invention relates generally to the field of steroids, and in particular, to new 11 ⁇ -substituted 19- norprogesterone analogs which possess antiprogestational or progestational activity.
• mefipristone had very significant antiglucocorticoid activity and was successfully used by Nieman et al (J. Clin. Endocrinology Metab. 61:536, 1985) in the treatment of Cushing's syndrome.
• mefipristone additionally exhibits a range of biological properties. Thus, for example, it exhibits growth-inhibitory properties towards estrogen-insensitive T47Dco human breast cancer cells (Horwitz, Endocrinology 116:2236, 1985).
• Experimental evidence suggests that the metabolic products derived from mefipristone contribute to its antiprogestational and antiglucocorticoid properties (Heikinheimo et al, J. Steroid Biochem. 26:279, 1987).
• one object of the present invention is to provide new steroid compounds having antiprogestational and/or antiglucocorticoidal properties.
• Another object of the invention is to provide novel steroids having progestational as well as antiprogestational activity.
• Figure 1 gives the structures of prior art compounds ZK 95.890, ZK 98.734 and ZK 98.299;
• FIG. 2 illustrates the structures of the compounds of the present invention. Best Mode For Carrying Out the Invention
• an 11 ⁇ -aryl substituent e.g. 11 ⁇ -(4-N,N-dimethylaminophenyl
• 11 ⁇ -aryl-19-norprogesterones of the present invention strong binding to the progesterone receptor may lead to either antiprogestational or progestational activity in vivo.
• the 11 ⁇ -substituted norprogesterone analogs of the present invention comprise compounds having structures A-C shown below.
• the compounds having structure A all contain a 16 ⁇ -hydrogen substituent (R 2 ) and a 17 ⁇ -acetyl substituent.
• the 16 ⁇ substituent (R 3 ) may be hydrogen, C 1-4 alkyl, C 2-4 alkenyl or C 2-4 alkynyl groups.
• the 17 ⁇ substituent (R 1 ) may be methyl, C 2-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, hydroxyl, OC(O)CH 3 (O-acetyl), or OC(O)R 5 , where R 5 is C 2-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl or aryl.
• Preferred compounds having structure A are those in which R 6 is N,N-dimethylamino or acetyl. Additional preferred compounds are those in which R 4 is hydrogen or methyl and R 1 is acetoxy or C 2-6 alkynyl groups. Specific examples of compounds having structure A are 17 ⁇ -acetoxy-6 ⁇ -methyl-11 ⁇ -(4-N,N-dimethylaminophenyl)- 19-norpregna-4,9-diene-3,20-dione, 17 ⁇ -acetoxy-11 ⁇ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 16 ⁇ -ethyl-11 ⁇ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 16 ⁇ -ethyl-6 ⁇ -methyl-11 ⁇ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,
• Compounds having structure B exhibit a carboncarbon double bond between C16 and C17.
• R 3 , R 4 , R 6 and X may be any of the groups defined above.
• Preferred compounds having structure B are compounds in which R 6 is an N,N-dimethylamino or an acetyl group.
• R 3 is H and R 4 is H or CH 3 .
• Specific examples of such compounds include 11 ⁇ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9,16-triene-3,20-dione and 11 ⁇ -(4-acetylphenyl)-19-norpregna-4,9,16-triene-3,20-dione.
• Preferred examples include compounds in which R 1 is acetoxy or C 2-8 alkynyl, R 4 is hydrogen or methyl and R 6 is dimethylamino or acetyl.
• Preferred aryl groups for R 5 in compounds A-C have the formula -C 6 H 4 -R 6 , in which R 6 has the same meaning as defined above.
• Steroids having progestational, antiprogestational and/or antiglucocorticoid activity have use in the control of fertility in humans and non-human mammals such as primates, domestic pets and farm animals, and in the treatment of ssedical conditions in animals or humans in which these activities are beneficial. Thus they may be useful in the treatment of conditions such as Cushing's syndrome, glaucoma, endometriosis, premenstrual syndrome and cancer in addition to their use in the control of reproduction.
• the compounds of the present invention may be administered by a variety of methods.
• those products of the invention that are active by the oral route may be administered in solutions, suspensions, emulsions, tablets, including sublingual and intrabuccal tablets, soft gelatin capsules, including solutions used in soft gelatin capsules, aqueous or oil suspensions, emulsions, pills, lozenges, troches, tablets, syrups or elixirs and the like.
• Products of the invention active on parenteral administration may be administered by depot injection, implants including SilasticTM and biodegradable implants, intramuscular and intravenous injections.
• compositions may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents. Tablets containing the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture of tablets are acceptable.
• excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
• inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate
• granulating and disintegrating agents such as maize starch, or alginic acid
• binding agents such
• Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
• an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin
• an oil medium such as peanut oil, liquid paraffin or olive oil.
• Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
• excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a
• the aqueous suspension may also contain one or more preservatives such as ethyl or npropyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin.
• preservatives such as ethyl or npropyl p-hydroxybenzoate
• coloring agents such as a coloring agent
• flavoring agents such as sucrose, aspartame or saccharin
• sweetening agents such as sucrose, aspartame or saccharin.
• Ophthalmic formulations as is known in the art, will be adjusted for osmotic pressure.
• Oil suspensions may be formulated by suspending the active incredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
• the oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
• Sweetening agents may be added to provide a palatable oral preparation.
• These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
• Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water may be formulated from the active ingredients in admixture with a dispersing, suspending and/or wetting agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
• the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
• the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
• Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate.
• the emulsion may also contain sweetening and flavoring agents.
• Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
• sweetening agents such as glycerol, sorbitol or sucrose.
• Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
• compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
• a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
• This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterallyacceptable diluent or solvent, such as a solution of 1,3-butanediol.
• the acceptable vehicles and solvents that may be employed are water and Ringer's solution, an isotonic sodium chloride.
• sterile fixed oils may conventionally be employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid may likewise be used in the preparation of inject
• compositions of this invention may also be administered in the form of suppositories for rectal administration of the drug.
• suppositories for rectal administration of the drug.
• These compositions can be prepared by mixing the drug with a suitable nonirritating excipient which is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug.
• suitable nonirritating excipient which is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug.
• Such materials are cocoa butter and polyethylene glycols.
• intranasal, intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations.
• Products of the invention which are preferably administered by the topical route may be administered as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
• Products having anti-glucocorticoid activity are of particular value in pathological conditions characterized by excess endogenous glucocorticoid such as Cushing's syndrome, hirsutism and in particular when associated with the adrenogenital syndrome, ocular conditions associated with glucocorticoid excess such as glaucoma, stress symptoms associated with excess glucocorticoid secretion and the like.
• Products having progestational activity are of particular value as progestational agents, ovulation inhibitors, menses regulators, contraceptive agents, agents for synchronization of fertile periods in cattle, endometriosis, and the like.
• estrogenic agents such as for example as ethynylestradiol or estradiol esters.
• Products having anti-progestational activity are characterized by antagonizing the effects of progesterone. As such, they are of particular value in control of hormonal irregularities in the menstrual cycle and for synchronization of fertile periods in cattle.
• the compounds of the invention may be used for control of fertility during the whole of the reproductive cycle. They are of particular value as postcoital contraceptives, for rendering the uterus inimical to implantation, and as "once a month" contraceptive agents. They may be used in conjunction with prostaglandins, oxytocics and the like.
• a further important utility for the products of the invention lies in their ability to slow down growth of hormone-dependent cancers.
• Such cancers include kidney, breast, endometrial, ovarian cancers, and prostate cancer which are characterized by possessing progesterone receptors and may be expected to respond to the products of this invention.
• Other utilities of anti-progestational agents include treatment of fibrocystic disease of the breast. Certain cancers and in particular melanomas may respond favorably to corticoid/anticorticoid therapy.
• the compounds according to the present invention may be administered to any warm-blooded mammal such as humans, domestic pets, and farm animals.
• domestic pets include dogs, cats, etc.
• Farm animals include cows, horses, pigs, sheep, goats, etc.
• the amount of active ingredient that may be combined with a carrier material to produce a single dosage form will vary depending upon the disease treated, the mammalian species, and the particular mode of administration.
• a unit dose of the steroid may preferably contain between 0.1 milligram and 1 gram of the active ingredient.
• a more preferred unit dose is between 0.001 and 0.5 grams.
• the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the art.
• the chloroform extracts (500 mL ⁇ 4) was dried over Na 2 SO 4 (anhydrous), filtered and concentrated to give 42 g of crude 6 ⁇ - methyl-17 ⁇ ,20 ⁇ ( ⁇ )- dihydroxy-pregna-1,4-dien-3-one.
• the product was shown to be a mixture of 20 ⁇ and 20 ⁇ -ol in a ratio of 85:15 based on 1 H NMR analysis.
• tetrahydrofuran 900 mL
• biphenyl 45 g, 0.29 mol
• diphenylmethane 50 mL, 0.285 mol
• the mixture was heated to reflux and lithium wire (3.5 g, 0.50 mol) was added in one portion.
• the resulting bluish-green solution of the complex was heated at gentle reflux for 16 h.
• An additional 0.5 g of lithium wire was added to maintain a dark-blue color.
• the diol (26 g, 0.076 mol) in 170 mL of THF was then added dropwise at such a rate that the blue color persisted throughout the addition.
• the reaction mixture was refluxed for an additional 45 min.
• the excess biphenyl lithium complex was quenched carefully with methanol in an ice-bath.
• THF was removed under reduced pressure and the product was extracted with CHCI 3 (500 mL ⁇ 3).
• the CHCI 3 extracts were combined, dried over sodium sulfate (anhydrous), filtered and concentrated to give 118 g of the crude product.
• the aqueous phase was acidified with HC1 solution (10% v/v) and extracted with CHCI 3 (500 mL ⁇ 2).
• Fraction A (4.0 g) was found to be 6 ⁇ -methyl-3-methoxy-19-norpregna-1,3,5(10)-triene-17 ⁇ ,20 ⁇ ( ⁇ )- diol.
• Fraction B (0.74 g) was found to be its 20 ⁇ -hydroxy isomer and
• Fraction C (0.54 g) was the recovered starting phenol.
• Liquid ammonia 35 mL was condensed into a flame dried three-neck round bottom flask equipped with a Dewar condenser and an additional funnel. Lithium wire (150 mg, 21.6 mmol) was added and the resulting bluish solution of the Li/NH 3 complex solution was stirred at -78°C for 1 hour. The above methyl ether (380 mg. 1.11 mmol) in 2.0 mL of dry THF and 1.0 mL of t-butanol was added dropwise. The blue color persisted throughout the addition. The resulting mixture was stirred at -78°C for an additional 45 minutes and quenched carefully with methanol until the blue color faded.
• the crude epoxide (3.4 g, 7.43 mmol) in dry tetrahydrofuran (25 mL) was added dropwise to a Grignard solution of p-N,N-dimethylaminophenylmagnesium bromide in the presence of dimethylsulfide cuprous bromide complex (1.8 g. 8.6 mmol).
• the Grignard mixture was prepared from p-bromo-N,N-dimethylaniline (14.0 g, 70 mmol) and magnesium (1.4 g, 57 mmol) in 150 mL of freshly distilled tetrahydrofuran.
• Example 1 Treatment of the latter (220 mg) with pyridinium hydrobromide perbromide by the procedure of Example 1 provided 22 mg of 20 ⁇ -isomer and 150 mg of 20 ⁇ -isomer of 20-hydroxy-6 ⁇ -methyl-16 ⁇ -ethyl-19-norpregna-4,9-dien-3-one.
• a preparative Rp-C18 column chromatography (20% H 2 O in MeOH) provided 7.0 mg of 6 ⁇ -methyl-16 ⁇ -ethyl-11 ⁇ -(4- N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and 2.5 mg of 6 ⁇ -methyl-16 ⁇ -ethyl-ll ⁇ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, together with 15 mg of unresolved mixture.
• Oxygen gas was slowly bubbled through a solution of the above olefin (0.33 g. 0.7 mmol) and hematoporphyrin (15 mg) in pyridine (7 mL), while the solution was irradiated with a fluorescent lamp (25 w) placed 7 cm from the reaction flask. After 3 days, the bubbling of oxygen was discontinued. To this reaction mixture was then added acetic anhydride (3 mL), and the solution stirred at room temperature for 2 hours.
• Example 1 By the procedure described in Example 1 for the synthesis of 6 ⁇ -methyl-11 ⁇ -(4-N,N-dimethylaminophenyl)- 3,3,20,20-bis(ethylenedioxy)-19-norpregn-g-ene-5 ⁇ , 17 ⁇ -diol from 6 ⁇ -methy1-3,3,20,20-bis(ethylenedioxy)-19-norpregna-5(10),9(11)-dien-17 ⁇ -ol, but substituting 2-(4-bromomagnesiumphenyl)-2,5,5-trimethyl-1,3-dioxane for p-N,N-dimethylaminophenylmagnesium bromide, 3,3-(ethylenedioxy)estra-5(10),9(11)-dien-17-one was converted to 3,3-ethylenedioxy-5 ⁇ -hydroxy-11 ⁇ -[4-(2,5,5-trimethyl-1,3-dioxan-2-yl)phenyl]estr-9-en-17-one
• Example 4 The latter compound was subjected to the procedures of Example 4 for converting 3,3-ethylenedioxy-11 ⁇ -(4-N,N-dimethylaminophenyl)-5 ⁇ - hydroxy-9-estren-17-one to 3,3-ethylenedioxy-11 ⁇ -(4-N,N-dimethylaminophenyl)-5 ⁇ -hydroxy-19-norpregna-9,16-dien-20-one followed by acid hydrolysis as described in Example 5 to yield 11 ⁇ -(4-acetylphenyl)-19-norpregna-4,9,16-triene-3,20-dione, m.p. around 194-197°C. Mass spectrum: m/z required for C 28 H 30 O 3 : 414.2195. Found: 414.2189.
• Example 9 In Vitro Binding to Receptors The in vitro activity of the subject compounds was determined by measuring the binding affinities (RBA) of these compounds relative to progesterone for the progesterone receptor in the cytosol obtained from estrogen-primed immature rabbit uterus and by measuring the RBA relative to dexamethasone for the glucocorticoid receptor from thymus of adrenalectomized rats. These assays were carried out by the procedures of J.R. Reel et al., Fertility and Sterility, 31, 552 (1979) (progesterone) and G.P. Chrousos et al., Endocrinology, 107, 472 (1980) (glucocorticoid). The results are presented in Table 1.
• the antiprogestational activity of the compounds was studied after both intrauterine and oral administration. In each case the compound was tested for its ability to inhibit the endometrial response due to subcutaneous administration of progesterone to estrogen-primed immature female rabbits.
• the methodology used for the intrauterine test has been described by D.A. McGinty et al. See Endocrinology, 24, 829 (1939).
• the method used was analogous to that of Clauberg. See Clauberg, Zentr. Gynakol., 54, 2757 (1930) as modified by McPhail J. Physiol. (London), 83, 145 (1935).
• the results of the intrauterine tests are given in Table 2.
• Each active compound was characterized by a dose-related ability to block the progestational effect of simultaneously administered progesterone.
• percent inhibition was plotted versus the log of the dose, linear relationships were obtained.
• Linear regression analysis permitted calculation of the ED 50 and ED 90 values (the doses required for 50% and 90% inhibition of the progesterone effect, respectively).
• the actual dose which gave 90% or more inhibition is also given, although this value is probably less accurate than the calculated values which are based on the dose-response line. Very unexpectedly, these results do not correlate well at all with the in vitro binding studies.
• the 17 ⁇ -acetoxy compounds also exhibited strong antiprogestational activity when given by the oral route, as is shown in Table 3 for 17 ⁇ -acetoxy-6 ⁇ -methyl-11 ⁇ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,g-diene-3,20-dione.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Urology & Nephrology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Reproductive Health (AREA)
• Emergency Medicine (AREA)
• Epidemiology (AREA)
• Steroid Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Control Of Eletrric Generators (AREA)
• Sub-Exchange Stations And Push- Button Telephones (AREA)
• Devices For Supply Of Signal Current (AREA)
• Light Receiving Elements (AREA)
• Led Devices (AREA)
• Junction Field-Effect Transistors (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Seasonings (AREA)
• Manufacture Of Tobacco Products (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22783162

Family Applications (1)

Country Status (13)

Cited By (20)

Families Citing this family (70)

Citations (1)

Family Cites Families (5)

• 1988
  • 1988-06-23 US US07/210,503 patent/US4954490A/en not_active Expired - Lifetime
• 1989
  • 1989-06-22 CA CA000603686A patent/CA1338906C/en not_active Expired - Lifetime
  • 1989-06-23 KR KR1019900700406A patent/KR0161975B1/ko not_active Expired - Lifetime
  • 1989-06-23 EP EP89907924A patent/EP0422100B1/en not_active Expired - Lifetime
  • 1989-06-23 AT AT89907924T patent/ATE149839T1/de active
  • 1989-06-23 DE DE68927861T patent/DE68927861T2/de not_active Expired - Lifetime
  • 1989-06-23 DE DE122009000031C patent/DE122009000031I2/de active Active
  • 1989-06-23 AU AU38506/89A patent/AU635211B2/en not_active Expired
  • 1989-06-23 WO PCT/US1989/002706 patent/WO1989012448A1/en not_active Ceased
  • 1989-06-23 JP JP1507392A patent/JP2953725B2/ja not_active Expired - Fee Related
• 1990
  • 1990-04-03 US US07/504,129 patent/US5073548A/en not_active Expired - Lifetime
  • 1990-12-21 NO NO905546A patent/NO178264C/no not_active IP Right Cessation
  • 1990-12-21 DK DK199003053A patent/DK175760B1/da active Protection Beyond IP Right Term
• 2009
  • 2009-06-03 LU LU91575C patent/LU91575I2/fr unknown
  • 2009-06-11 NL NL300392C patent/NL300392I2/nl unknown
  • 2009-06-22 NO NO2009014C patent/NO2009014I2/no unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events